RT Journal Article
SR Electronic
T1 No clear evidence for relationships of Apolipoprotein E genotype with measures of common infections in three UK cohorts
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.17.24302569
DO 10.1101/2024.02.17.24302569
A1 Green, Rebecca E.
A1 Fernández-Sanlés, Alba
A1 Felici, Caterina
A1 Warren-Gash, Charlotte
A1 Butt, Julia
A1 Waterboer, Tim
A1 Richards, Marcus
A1 Schott, Jonathan M.
A1 Hughes, Alun D.
A1 Chaturvedi, Nish
A1 Williams, Dylan M.
YR 2024
UL http://medrxiv.org/content/early/2024/02/18/2024.02.17.24302569.abstract
AB APOE genotype is the strongest genetic risk factor for late onset Alzheimer’s disease, with the ε2 and ε4 alleles decreasing and increasing risk relative to the ε3 allele, respectively. Although evidence has been conflicting, several common infections have been associated with Alzheimer’s disease risk, and interactions by APOE ε4 carriage have also been reported. Nevertheless, to date, no study has examined relationships between APOE genotype and measures of multiple common infections among large population-based studies.We investigated associations of APOE ε2 and ε4 carriage (i.e. non-carrier vs carrier) with serostatus and antibody titers to 14 common pathogens – encompassing herpesviruses, human polyomaviruses, C.trachoma,t iHs.pylor,i and T.gond i i– in three population-based cohorts (UK Biobank, National Survey of Health and Development, Southall and Brent Revisited). Pathogen serostatus was derived using validated antibody cut-offs for relevant antigens and included as an outcome assessing previous infection. Antibody titers were dichotomised among the seropositive subset for each antigen and included as binary outcomes assessing recent immunological responses. We conducted analyses in each cohort using mixed-models, including age, sex and genetic principal components as fixed-effects, and genetic relatedness as a random-effect. In secondary analyses, we additionally assessed i) relationships of APOE ε2 and ε4 dosage (i.e. number of copies of the allele of interest), and ii) relationships of APOE genotype with continuous antibody titers (rank-based inverse normal transformed). Findings were meta-analysed across cohorts (n=10,059) using random-effects models and corrected for multiple tests using the false discovery rate.We found no clear evidence of relationships between APOE genotype and serostatus or antibody titers to any pathogen, with no strong associations observed in any of our analyses following multiple testing correction. Investigations of APOE genotypes with the clinical manifestations of these pathogens, as well as expanding to include other viruses such as SARS-CoV-2, would also be warranted.Competing Interest StatementJMS has received research funding and PET tracer from AVID Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly) and Alliance Medical; has consulted for Roche, Eli Lilly, Biogen, AVID, Merck and GE; and received royalties from Oxford University Press and Henry Stewart Talks. He is Chief Medical Officer for Alzheimer's Research UK. NC receives funds from AstraZeneca for serving on data safety and monitoring committees for clinical trials of glucose lowering agents.Funding StatementThis research was supported by funding from the British Heart Foundation (PG/21/10776), the UK Medical Research Council (MC_UU_00019/1; MC_UU_00019/2; MC_UU_00019/3) and Open Philanthropy. CWG is supported by a Wellcome Career Development Award (225868/Z/22/Z).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All cohorts received ethical approval and all participants provided written informed consent. The NSHD and its sub-study Insight 46 received approval from the National Research Ethics Service Committee London (14/LO/1173), SABRE from the St Mary's Hospital Research Ethics Committee (07/H0712/109), and UKB from the NHS North West Research Ethics Committee (11/NW/0382).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesPer-study results are available on request.